RM Lago, PP Singh, RW Nesto - The Lancet, 2007 - Elsevier 360 of 20 191 patients who had either prediabetes or type 2 diabetes had
congestive heart failure events (214 with TZDs and 146 with comparators).
Results showed no heterogeneity of effects across studies (I 2 =22·8%; p ... Cited by 180 - Related articles - BL Direct - All 7 versions
GGL Biondi-Zoccai, M Lotrionte, M Anselmino, … - American heart journal, 2008 - Elsevier A total of 23 RCTs were included (5428 patients), with median follow-up of 6
months. Pooled analysis showed that cilostazol was associated with statistically
significant reductions in binary angiographic restenosis (RR = 0.60 ... Cited by 26 - Related articles - All 27 versions
- ►procampus.net [PDF] - Free from Publisher ZT Bloomgarden - Diabetes Care, 2007 - Am Diabetes Assoc Perspectives on the News commentaries are now part of a new, free monthly CME
activity. The Mount Sinai School of Medicine, New York, New York, is designating
this activity for 2.0 AMA PRA Category 1 credits. If you wish to ... Cited by 18 - Related articles - BL Direct - All 7 versions
- ►nursing2008.com E Mannucci, M Monami, C Lamanna, GF … - Diabetes, Obesity and Metabolism, 2008 - pt.wkhealth.com Aim: The aim of this meta-analysis of randomized clinical trials (RCT) was to
assess whether pioglitazone is also associated with increased cardiovascular
risk, as recently reported for rosiglitazone. Methods: RCT of pioglitazone ... Cited by 14 - Related articles - All 6 versions
A Pfützner, MM Weber, T Forst - Expert Opin. Pharmacother., 2007 - informahealthcare.com Pioglitazone, a member of the PPAR-γ agonist drug family, has been demonstrated
to improve both metabolic and vascular insulin resistance when applied to
patients with Type 2 diabetes mellitus. The drug is well tolerated with ... Cited by 12 - Related articles - BL Direct - All 5 versions
M Monami, N Marchionni, E Mannucci - Diabetes Research and Clinical Practice, 2008 - Elsevier The treatment with rosiglitazone could be associated with increased risk for
myocardial infarction (MI). This meta-analysis is aimed at identifying
moderators of the effect of rosiglitazone on the risk of MI and chronic ... Cited by 7 - Related articles - All 18 versions
RA Ajjan, PJ Grant - Expert Opin. Drug Saf., 2008 - informahealthcare.com Background: Thiazolidinediones (rosiglitazone, pioglitazone) influence insulin
sensitivity and are used for the treatment of Type 2 diabetes. Rosiglitazone
achieves sustained improvements in glycaemic control, whilst having ... Cited by 6 - Related articles - All 7 versions
D Geng, D Jin, W Wu, Z Wang, J Wang - Atherosclerosis, 2009 - Elsevier We performed a meta-analysis of all relevant randomized controlled trials to
evaluate the effect of TZDs therapy on in-stent restenosis in patients
undergoing coronary stenting. Eight trials involving 366 patients were ... Cited by 5 - Related articles - All 29 versions
- ►diabetesjournals.org ZT Bloomgarden - Diabetes Care, 2008 - Am Diabetes Assoc At the American Diabetes Association (ADA) Postgraduate Course, Ralph DeFronzo
(San Antonio, TX) reviewed the mechanisms of action and utility of various
antidiabetic drugs, suggesting that sulfonylureas “are very unlikely to ... Cited by 4 - Related articles - All 7 versions
